JP2010527607A5 - - Google Patents

Download PDF

Info

Publication number
JP2010527607A5
JP2010527607A5 JP2010509392A JP2010509392A JP2010527607A5 JP 2010527607 A5 JP2010527607 A5 JP 2010527607A5 JP 2010509392 A JP2010509392 A JP 2010509392A JP 2010509392 A JP2010509392 A JP 2010509392A JP 2010527607 A5 JP2010527607 A5 JP 2010527607A5
Authority
JP
Japan
Prior art keywords
domain
peptide
protein
composition
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010509392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527607A (ja
JP5591691B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/006593 external-priority patent/WO2008153745A2/en
Publication of JP2010527607A publication Critical patent/JP2010527607A/ja
Publication of JP2010527607A5 publication Critical patent/JP2010527607A5/ja
Application granted granted Critical
Publication of JP5591691B2 publication Critical patent/JP5591691B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010509392A 2007-05-22 2008-05-22 生物活性を有する融合タンパク質を作製するための組成物及び方法 Expired - Fee Related JP5591691B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93134407P 2007-05-22 2007-05-22
US60/931,344 2007-05-22
PCT/US2008/006593 WO2008153745A2 (en) 2007-05-22 2008-05-22 Compositions and methods for producing bioactive fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013230035A Division JP2014064575A (ja) 2007-05-22 2013-11-06 生物活性を有する融合タンパク質を作製するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2010527607A JP2010527607A (ja) 2010-08-19
JP2010527607A5 true JP2010527607A5 (enExample) 2011-06-30
JP5591691B2 JP5591691B2 (ja) 2014-09-17

Family

ID=40130377

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010509392A Expired - Fee Related JP5591691B2 (ja) 2007-05-22 2008-05-22 生物活性を有する融合タンパク質を作製するための組成物及び方法
JP2013230035A Withdrawn JP2014064575A (ja) 2007-05-22 2013-11-06 生物活性を有する融合タンパク質を作製するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013230035A Withdrawn JP2014064575A (ja) 2007-05-22 2013-11-06 生物活性を有する融合タンパク質を作製するための組成物及び方法

Country Status (7)

Country Link
US (3) US8420779B2 (enExample)
EP (2) EP2162540A2 (enExample)
JP (2) JP5591691B2 (enExample)
AU (1) AU2008262490B2 (enExample)
CA (2) CA2840407A1 (enExample)
MX (1) MX2009012609A (enExample)
WO (1) WO2008153745A2 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121743B1 (en) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
CN101977932B (zh) 2008-01-31 2014-09-03 美国政府健康及人类服务部 工程化抗体恒定结构域分子
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之egfr/igfir結合分子
ES2573108T3 (es) 2010-05-26 2016-06-06 Bristol-Myers Squibb Company Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
KR102025848B1 (ko) 2010-12-01 2019-11-05 앨더바이오 홀딩스 엘엘씨 항―ngf 조성물 및 그의 용도
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
LT3564258T (lt) 2012-09-13 2021-08-25 Bristol-Myers Squibb Company Karkasiniai domeniniai baltymai fibronektino pagrindu, kurie jungiasi su miostatinu
WO2014094799A1 (en) * 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
MX365987B (es) * 2013-01-25 2019-06-20 Janssen Biotech Inc Antagonistas de kv1.3 y métodos de uso.
US10787498B2 (en) 2013-02-06 2020-09-29 Bristol-Myers Squibb Company Fibronectin type III domain proteins with enhanced solubility
EP3299378B1 (en) * 2013-02-12 2019-07-31 Bristol-Myers Squibb Company High ph protein refolding methods
CN104046600B (zh) * 2013-12-30 2019-04-05 江苏众红生物工程创药研究院有限公司 多臂聚乙二醇修饰剂的新用途及其在修饰门冬酰胺酶中的应用
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20170252417A1 (en) * 2016-03-07 2017-09-07 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
ES2934129T3 (es) * 2016-03-25 2023-02-17 Univ Osaka Vacuna conjugada dirigida a una proteína biológica causante de enfermedad
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2018266705B2 (en) 2017-05-08 2023-05-04 Seattle Project Corp. Alphavirus neoantigen vectors
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
CN118955720A (zh) 2018-01-04 2024-11-15 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
WO2019179361A1 (zh) * 2018-03-21 2019-09-26 傅惠芳 改善括约肌闭锁不全的组合物及其医药组成物与用途
BR112021024127A2 (pt) 2019-05-30 2022-04-26 Gritstone Bio Inc Adenovírus modificado
EP4003906A4 (en) * 2019-07-30 2024-03-06 Academia Sinica Peptide-loaded carrier systems and uses thereof
MX2022005916A (es) * 2019-11-19 2022-08-04 Asklepios Biopharmaceutical Inc Virus adenoasociado terapeutico que comprende promotores especificos del higado para el tratamiento de la enfermedad de pompe y los trastornos liposomales.
CN116438308A (zh) 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒
WO2022065913A1 (ko) 2020-09-25 2022-03-31 주식회사 프로앱텍 요산산화효소-알부민 접합체, 그 제조방법 및 용도
WO2022065936A1 (ko) * 2020-09-25 2022-03-31 주식회사 프로앱텍 기능성 폴리펩티드 변이체의 컨쥬게이트 및 그 용도
WO2023215837A2 (en) * 2022-05-04 2023-11-09 Ohio State Innovation Foundation Compositions for delivery of agents into plant cells

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US3941763A (en) * 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4083368A (en) * 1976-09-01 1978-04-11 Freezer Winthrop J Inhaler
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US5002936A (en) 1985-04-12 1991-03-26 Seymour Lieberman Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
JPH0669959B2 (ja) 1985-09-26 1994-09-07 東燃株式会社 コレラ毒素類を活性成分とする免疫抑制剤
JP2876058B2 (ja) 1986-08-18 1999-03-31 エミスフィア・テクノロジーズ・インコーポレイテッド 薬物送達システム
AU607172B2 (en) 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH01502909A (ja) 1987-02-24 1989-10-05 ゾーマ・コーポレーション 免疫毒素による人間の治療における免疫抑制
ATE106249T1 (de) 1987-11-05 1994-06-15 Hybritech Inc Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
US4849224A (en) 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4983395A (en) * 1987-11-12 1991-01-08 Theratech Inc. Device for administering an active agent to the skin or mucosa
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
DE68925893T2 (de) 1988-07-23 1996-08-08 Delta Biotechnology Ltd Sekretorische leader-sequenzen
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
CN1071436A (zh) * 1988-12-19 1993-04-28 约翰·J·曼斯特 木质素-丙烯酰胺-苯乙烯接枝共聚物,制法及应用
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
US4906159A (en) * 1989-03-22 1990-03-06 Caterpillar Industrial Inc. Freely positionable load carrying attachment for an automatic guided vehicle
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6267964B1 (en) * 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
IL98932A0 (en) 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0575545B1 (en) 1991-03-15 2003-05-21 Amgen Inc. Pegylation of polypeptides
CA2082951C (en) 1991-03-15 1999-12-21 Robert M. Platz Pulmonary administration of granulocyte colony stimulating factor
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
SE9201073D0 (sv) 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5494895A (en) 1993-07-22 1996-02-27 Merck & Co., Inc. Scorpion peptide margatoxin with immunosuppressant activity
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
JPH08140677A (ja) * 1994-01-28 1996-06-04 Science & Tech Agency キメラ蛋白質およびその製造法
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
FI963185L (fi) 1994-02-14 1996-08-14 Zymogenetics Inc Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi
CA2184002A1 (en) * 1994-02-23 1995-08-31 Jeffrey M. Blaney Method and compositions for increasing the serum half-life of pharmacologically active agents
FR2717688B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
WO1995026746A1 (en) 1994-03-31 1995-10-12 Amgen Inc. Compositions and methods for stimulating megakaryocyte growth and differentiation
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2208132A1 (en) 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
CZ288146B6 (en) 1994-12-22 2001-05-16 Astra Ab Pharmaceutical aerosol preparation, process of its preparation and use
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5746516A (en) 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
US5849863A (en) 1995-09-08 1998-12-15 University Of Colorado Cytolytic bradykinin antagonists
US5834431A (en) 1995-09-08 1998-11-10 Cortech, Inc. Des-Arg9 -BK antagonists
US7288254B2 (en) 1995-10-30 2007-10-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5763478A (en) * 1996-10-16 1998-06-09 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US6077680A (en) * 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
ATE307829T1 (de) * 1996-12-26 2005-11-15 Suntory Ltd Skorpion-spezifische neuropeptide
CA2284079C (en) 1997-03-05 2009-05-12 David M. Neville Immunotoxins and methods of inducing immune tolerance
WO2000055371A1 (en) 1999-03-18 2000-09-21 Human Genome Sciences, Inc. 27 human secreted proteins
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
HU230547B1 (hu) 1997-04-16 2016-11-28 Amgen Inc. Osteoprotegerin-kötő fehérjék és receptorok
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5985608A (en) 1997-10-31 1999-11-16 University Of Massachusetts Actin-binding polypeptides and nucleic acids encoding the same
SG129211A1 (en) 1997-11-06 2007-02-26 Univ Singapore Therapeutic molecules
US6551821B1 (en) * 1997-12-23 2003-04-22 The Trustees Of Columbia University In The City Of New York Brain cyclic nucleotide gated ion channel and uses thereof
US6703485B2 (en) * 1997-12-23 2004-03-09 The Trustees Of Columbia University In The City Of New York Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
AU2333999A (en) 1998-01-23 1999-08-09 Prolifaron, Inc. Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors
JP3530004B2 (ja) * 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
US6022952A (en) * 1998-04-01 2000-02-08 University Of Alberta Compositions and methods for protein secretion
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
SK287737B6 (sk) 1998-10-23 2011-08-04 Kirin-Amgen Inc. Peptidová zlúčenina, spôsob jej výroby a použitie, farmaceutický prostriedok, polynukleotid, vektor a hostiteľská bunka
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7029909B1 (en) 1998-11-20 2006-04-18 Fuso Pharmaceutical Industries, Ltd. Protein expression vector and utilization thereof
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU769610B2 (en) 1998-12-23 2004-01-29 Amgen, Inc. Polyol/oil suspensions for the sustained release of proteins
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ATE318835T1 (de) 1999-05-17 2006-03-15 Conjuchem Inc Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6768002B1 (en) * 1999-06-22 2004-07-27 E. I. Du Pont De Nemours And Company Scorpion toxins
EP1185654A2 (en) * 1999-06-22 2002-03-13 E.I. Du Pont De Nemours And Company Scorpion toxins from buthotus judaicus
US6096891A (en) * 1999-12-09 2000-08-01 Air Products And Chemicals, Inc. Process for the production of cyclic N,N'-dialkylureas
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
SE0000935D0 (sv) 2000-03-21 2000-03-21 Astrazeneca Ab An inhalation device
AU2001264563A1 (en) * 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CA2407956A1 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
EP1177806A1 (en) 2000-08-04 2002-02-06 The Technology Partnership Public Limited Company Dry powder inhaler
EP1315747B1 (en) * 2000-09-04 2006-03-29 Cellpep S.A. Maurotoxin, pi1 and hstx1 derivatives
ES2361824T3 (es) 2000-12-20 2011-06-22 F. Hoffmann-La Roche Ag Conjugados de eritropoyetina (epo) con polietilenglicol (peg).
JP5013152B2 (ja) * 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
EP1377306A1 (en) * 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002085821A2 (en) * 2001-04-24 2002-10-31 Shell International Research Maatschappij B.V. In situ recovery from a relatively permeable formation containing heavy hydrocarbons
JP4516719B2 (ja) 2001-05-11 2010-08-04 アムジエン・インコーポレーテツド Tall−1と結合するペプチド及び関連分子
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6861405B2 (en) 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
PL211116B1 (pl) * 2001-10-19 2012-04-30 Idexx Lab Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7071172B2 (en) * 2002-04-30 2006-07-04 The University Of North Carolina At Chapel Hill Secretion signal vectors
GB0219512D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions with high drug ratios
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
CA2499300A1 (en) * 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
AU2003285200A1 (en) 2002-11-09 2004-06-03 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
KR20150107899A (ko) 2002-12-20 2015-09-23 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
PL1641483T3 (pl) 2003-06-12 2008-07-31 Lilly Co Eli Białka fuzyjne
JP4055010B2 (ja) * 2003-09-26 2008-03-05 セイコーエプソン株式会社 画像処理システム、プロジェクタ、プログラム、情報記憶媒体および画像処理方法
US7605120B2 (en) 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
RU2352583C2 (ru) 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
WO2005058956A1 (en) * 2003-12-16 2005-06-30 Commonwealth Scientific And Industrial Research Organisation Cytokine binding domains
JP4315982B2 (ja) 2004-01-09 2009-08-19 ファイザー インコーポレイティッド MAdCAMに対する抗体
US7323169B2 (en) 2004-04-23 2008-01-29 Amgen Inc. Sustained release formulations
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
WO2006137836A2 (en) * 2004-08-17 2006-12-28 Research Development Foundation Bacterial vector systems
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
MX2007004074A (es) 2004-10-07 2007-08-14 Univ California Analogos de toxina shk y sus usos en inhibicion selectiva de canales de potasio kv1.3.
US20060199812A1 (en) 2005-01-24 2006-09-07 Amgen Inc. Method of conjugating aminothiol containing molecules to vehicles
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP1909838A2 (en) * 2005-07-29 2008-04-16 Amgen Inc. Formulations that inhibit protein aggregation
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007047577A2 (en) 2005-10-14 2007-04-26 The Board Of Trustees Of The University Of Illinois Use of calcitonin-related peptide (cgrp) antagonists or release inhibitors for the treatment of sleep-related breathing disorders
TW200722436A (en) 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
WO2008088422A2 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins

Similar Documents

Publication Publication Date Title
JP2010527607A5 (enExample)
ES2667558T3 (es) Polipéptidos de fusión que comprenden una proteína activa unida a un polipéptido con dominio mucina
TWI250988B (en) Thrombopoietic compounds
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP5211109B2 (ja) 膜転位剤および製薬学的有効成分の複合物
AU2013285470B2 (en) Conjugates containing sequences from placenta growth factor and their use as components of biomaterials and in medicine
Wu et al. Optimization of protein and peptide drugs based on the mechanisms of kidney clearance
JP2005509609A5 (enExample)
CN101124331A (zh) Fⅷ的位点定向修饰
RS58948B1 (sr) Prolek koji sadrži linker koji se može sam odcepiti
US20070025965A1 (en) Therapies for renal failure using interferon-beta
ES2690147T3 (es) Apelina pegilada y usos de la misma
AU1179895A (en) Improved interferon polymer conjugates
JP2012140466A (ja) ポリ(エチレングリコール)修飾ペプチド系化合物の新規スペーサー部分
WO2002077036A2 (en) Recombinant production of polyanionic polymers, and uses thereof
JP2017200930A (ja) HMBG1のBox−AおよびHMGB1のBox−A変異体のポリマー複合体
CA2660615A1 (en) G-csf site-specific mono-conjugates
JP2012504965A5 (enExample)
JP2010529860A5 (enExample)
KR20150113934A (ko) 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
EP2495258B1 (en) Catechol polyethylene glycol derivative and protein or peptide conjugates, and method for preparing same
WO2008051383A2 (en) Use of alcohol co-solvents to improve pegylation reaction yields
CN101528266B (zh) Hmgb1的a盒和hmgb1的a盒变体的聚合体缀合物
AU2020281098B2 (en) Methods and compositions for treatment of cartilage damage and arthritis
KR101042965B1 (ko) 카테콜 폴리에틸렌글리콜 유도체와 단백질 또는 펩타이드의 접합체 및 이의 제조방법